Article in Human mutation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Christina A EichstaedtCenter for Pulmonary Hypertension, Thoraxklinik-Heidelberg gGmbH, Heidelberg University Hospital and Translational Lung Research Center (TLRC), German Center for Lung Research (DZL), Heidelberg, Baden-Württemberg, Germany.ORCID 0000-0001-7288-8297
Gabriel Maldonado-VelezDivision of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0009-0004-6409-2626
Rajiv D MachadoSchool of Health & Medical Sciences, City St George's, University of London, London, UK.ORCID 0000-0001-9247-0744
Stefan GräfDepartment of Medicine, School of Clinical Medicine, University of Cambridge, Victor Phillip Dahdaleh Heart & Lung Research Institute, Cambridge, UK.ORCID 0000-0002-1315-8873
Dennis DooijesDepartment of Genetics, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Srimmitha BalachandarDivision of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-0767-4388
Florence CouletSaint-Antoine Research Centre, Sorbonne University, Paris, France.
Kristina DayDivision of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0001-9481-8548
Melanie EyriesGenetics Department, AP-HP Sorbonne University, Paris, France.
Daniela MacayaGeneDx Inc., Gaithersburg, Maryland, USA.
Memoona ShaukatCenter for Pulmonary Hypertension, Thoraxklinik-Heidelberg gGmbH, Heidelberg University Hospital and Translational Lung Research Center (TLRC), German Center for Lung Research (DZL), Heidelberg, Baden-Württemberg, Germany.
Laura SouthgateSchool of Health & Medical Sciences, City St George's, University of London, London, UK.ORCID 0000-0002-2090-1450
Jair Tenorio-CastanoInstitute of Medical and Molecular Genetics (INGEMM), La Paz University Hospital, IDiPAZ, Autonoma University of Madrid, Madrid, Spain.ORCID 0000-0002-5308-2316
Wendy K ChungDivision of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-3438-5685
Carrie L WelchDivision of Genetics and Genomics, Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0003-3521-4458
Micheala A AldredDivision of Pulmonary, Critical Care, Sleep and Occupational Medicine, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.ORCID 0000-0002-7390-9181
Funding
Genomics of Pulmonary Vascular DiseaseR35HL140019 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI ALDRED, MICHEALA A · 2018 to 2024
$5.6M
NHLBI NIH HHS R35 HL140019
6 · The paper itself
Abstract
Pulmonary arterial hypertension (PAH) is a rare disease that can be caused by pathogenic variants, most frequently in the bone Morphogenetic Protein Receptor Type 2 (
Indexed as
Bone Morphogenetic Protein Receptors, Type IIGenetic VariationHypertension, PulmonaryMutationPulmonary Arterial HypertensionGenetic Predisposition to DiseaseHumansPractice Guidelines as TopicRNA SplicingBMPR2 protein, humanBone Morphogenetic Protein Receptors, Type IIACMG/AMP guidelinesBMPR2ClinVarpulmonary arterial hypertensionvariant interpretation
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Adaptation of ACMG/AMP Guidelines for Clinical Classification of · full record | OpenQuestion